Monday, October 3, 2016

Alphosyl HC Cream





1. Name Of The Medicinal Product



Alphosyl HC Cream


2. Qualitative And Quantitative Composition










Allantoin




2.0% w/w




Alcoholic Extract of Coal Tar




5.0% w/w




Hydrocortisone




0.5%



3. Pharmaceutical Form



Cream for topical application.



4. Clinical Particulars



4.1 Therapeutic Indications



For the treatment of psoriasis by topical administration.



4.2 Posology And Method Of Administration



For all patients, apply cream sparingly twice daily to psoriatic plaques - rub in well until the cream is no longer visible.



Not recommended for children under 5 years.



4.3 Contraindications



Tuberculosis or fungal lesions of the skin (e.g. athlete's foot), acne vulgaris, herpes simplex (cold sores), vaccinia or varicella, and a history of hypersensitivity to any of the ingredients.



Not for use in sore, acute or pustular psoriasis or in the presence of infection.



4.4 Special Warnings And Precautions For Use



For external use only.



Avoid contact with the eyes. Avoid mucosa, genital or rectal areas and broken or inflamed skin.



Use sparingly, discontinue use if sensitivity occurs.



The following results of steroid use are uncommon at this dosage



However:



- When used over large areas or for prolonged periods systemic side effects can result.



- Under occlusive dressings or intertriginous areas topical steroids may cause skin atrophy manifesting as striae, thinning and telangiectesia.



- Viral, bacterial or fungal infection of the skin may be substantially exacerbated by topical steroid treatment unless accompanied by appropriate therapy.



- Wound healing can be significantly retarded.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



None



4.6 Pregnancy And Lactation



Topical administration of corticosteroids to pregnant animals can cause abnormality of foetal development. Topical steroids should not be used extensively during pregnancy, i.e. in large amounts or for long periods because of the risk of teratogenic effects or significant absorption causing suppression of the HPA axis.



4.7 Effects On Ability To Drive And Use Machines



None



4.8 Undesirable Effects



Adverse events derived from post-marketing data are tabulated below by system organ class. The frequency of these adverse events is not known (cannot be estimated from the available data).










Body System




Undesirable effect




Immune system disorders




Hypersensitivity (including rash, itching, dyspnoea and angioedema)



Allergic reactions*




Skin and subcutaneous tissue disorders




Skin irritation and acne like eruptions



Photosensitivity



*Allergic reactions may be delayed.



4.9 Overdose



Not applicable



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Coal tar is a standard antipruritic and keratoplastic agent used in the treatment of psoriasis and other skin affections.



Allantoin is a chemical dedrider; stimulates cell proliferation, epithelization and granulation, and hence hastens wound healing.



Steroids are standard in the treatment of various skin disorders.



5.2 Pharmacokinetic Properties



Not applicable



5.3 Preclinical Safety Data



Several animal studies have demonstrated that the non-carcinogenic toxicity profile of medicinal coal tar is acceptable.



Coal tar preparations have been shown to contain chemicals with a known relationship to the development of malignant tumours in experimental models. Animal studies, where coal tar has been applied topically, have consistently given positive results.



However, it is consistently clear that epidemiological studies in man have not confirmed this carcinogenic potential. Where isolated case studies have related the use of medicinal coal tar to tumour induction, well controlled retrospective studies have not confirmed the relationship. The individual case reports are not well documented as to causation.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Beeswax Yellow



Cetyl Alcohol



Citric Acid



Maize Oil



Glycerol Monostearate



Isopropyl Palmitate



Liquid Base CB 3929



Methyl Hydroxybenzoate



Oleyl Alcohol



Propyl Gallate



Propyl Hydroxybenzoate



PEG-400 Dilaurate



Sodium Citrate



Sqaulene



Lecithin, Vegetable



Triethanolamine



Phenethyl Alcohol



Water Purified



6.2 Incompatibilities



None known



6.3 Shelf Life



18 months



6.4 Special Precautions For Storage



Store between 4°C and 25°C



6.5 Nature And Contents Of Container



Alphosyl HC Cream is packaged in decorated, 30 g or 100 g collapsible aluminium tubes with a phenolic/epoxy resin liner and latex end seal. The nozzle is closed with a high density polyethylene screw on cap.



6.6 Special Precautions For Disposal And Other Handling



For all patients, apply sparingly twice a day to psoriatic plaques and rub in well until the cream is no longer visible. Alphosyl HC Cream is not recommended for children under 5 years.



7. Marketing Authorisation Holder



Stafford-Miller Limited



980 Great West Road



Brentford, Middlesex



TW8 9GS



United Kingdom



Trading as: GlaxoSmithKline Consumer Healthcare, Brentford TW8 9GS, UK



8. Marketing Authorisation Number(S)



PL 00036/0026R



9. Date Of First Authorisation/Renewal Of The Authorisation



17/1/1997



10. Date Of Revision Of The Text



11/03/2011





No comments:

Post a Comment